Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
1. A therapeutic composition comprising a BMP-9 peptide in a fusion with an elastin-like peptide (ELP) comprising at least 90 repeating units of VPGXG (SEQ ID NO: 3) and a pharmaceutically acceptable carrier or excipient, and wherein the fusion protein exhibits an increased half-life in serum compared to an unfused BMP-9 peptide.
2. The therapeutic composition of claim 1 , wherein each X is independently selected from alanine, glycine, and valine residues.
3. The therapeutic composition of claim 1 , wherein the elastin-like peptide comprises at least 120 repeating units of VPGXG (SEQ ID NO: 3), wherein X is Val, Ala, or Gly at a ratio of 5:2:3.
4. The therapeutic composition of claim 1 , wherein the elastin-like peptide comprises at least 144 repeating units of VPGXG (SEQ ID NO: 3).
5. The therapeutic composition of claim 1 , wherein the BMP-9 peptide is positioned at the N-terminal end of the ELP component.
6. The therapeutic composition of claim 1 , wherein the composition is formulated for parenteral administration.
7. The therapeutic composition of claim 1 , wherein the composition is formulated for subcutaneous administration.
8. The therapeutic composition of claim 1 , wherein the composition is formulated for systemic delivery.
9. A therapeutic composition comprising a BMP-9 peptide in a fusion with an elastin-like peptide (ELP) comprising 120 repeating units of VPGXG (SEQ ID NO: 3) wherein X is Val, Ala, or Gly at a ratio of 5:2:3 and a pharmaceutically acceptable carrier or excipient, and wherein the fusion protein exhibits an increased half-life in serum compared to an unfused BMP-9 peptide.
10. A therapeutic composition comprising a BMP-9 peptide in a fusion with an elastin-like peptide (ELP) comprising 144 repeating units of VPGXG (SEQ ID NO: 3) and a pharmaceutically acceptable carrier or excipient, and wherein the fusion protein exhibits an increased half-life in serum compared to an unfused BMP-9 peptide.